Conversion of Yorkville’s Convertible Notes into shares
The Board of Directors of Panion Animal Health AB (the “Company” or “Panion”) has, pursuant to the terms and conditions of the financing arrangement between Panion and an investment fund managed by Yorkville Advisors Global (“Yorkville”) announced on 9 January 2018, resolved to approve the request of Yorkville to convert a proportion of SEK 200,000 of the convertible notes to shares in the Company at conversion price of SEK 1.40 per share. The conversion shall be executed by issuing a total of 142,857 shares to Yorkville. After the transfer the Company will have in total 16 349 450 shares. To facilitate a swift and timely conversion, Yorkville has, pursuant to the terms and conditions of the financing programme, received loan shares while awaiting the registration and issuing of the new shares. Upon receiving the issued shares, the loan shares will then be replenished.
Board of Directors Panion Animal Health AB
This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion’s CEO, Anja E. H. Holm, for publication on March 14 2018.
Anja E. H. Holm, CEO
+ 45-22 94 66 00
Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.